Market Overview
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 90.60 Billion |
| Market Size (2030) | USD 107.66 Billion |
| Growth Rate (2025 - 2030) | 3.51% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Diabetes Drugs Market Analysis by Mordor Intelligence
The diabetes drugs market generated USD 90.6 billion in 2025 and is forecast to reach USD 107.66 billion by 2030, advancing at a 3.51% CAGR. Sustained growth is rooted in the accelerating global diabetes burden, earlier diagnosis, and rapid uptake of innovative therapies that combine glycemic control with weight-management benefits. Insulin remains indispensable, yet demand is tilting toward GLP-1 receptor agonists and other non-insulin injectables that improve cardiometabolic outcomes [1]Youngmin Kwon, “State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar,” JAMA Health Forum, jamanetwork.com. Oral peptide technologies, biosimilar basal insulins, and digitally enabled care models are widening patient access while tempering costs. Competitive intensity is high as incumbents scale manufacturing and digital ecosystems to defend share in an increasingly value-driven environment.
Key Report Takeaways
- By drug class, insulin products captured 55% of diabetes drugs market share in 2024; GLP-1 receptor agonists are projected to expand at a 4.5% CAGR between 2025-2030.
- By route of administration, the subcutaneous segment accounted for 72% of the diabetes drugs market size in 2024, whereas the oral segment is set to grow at a 4.8% CAGR through 2030.
- By geography, North America held 42% of the diabetes drugs market share in 2024, while Asia-Pacific is poised for the fastest growth at a 5.3% CAGR to 2030.
Global Diabetes Drugs Market Trends and Insights
Driver Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Escalating Global Diabetes Prevalence and Early Diagnosis | +1.2% | Global, with higher impact in Asia-Pacific and Middle East | Long term (≥ 4 years) |
| Escalating global diabetes prevalence & early diagnosis | +1.2% | Global; strongest in Asia-Pacific & Middle East | Long term (≥ 4 years) |
| Rising healthcare expenditures | +0.8% | North America, Europe, developed Asia-Pacific | Medium term (2-4 years) |
| Rise of combination fixed-dose pens | +0.5% | North America, Europe, Japan | Medium term (2-4 years) |
| Strong outcome-based clinical evidence and guideline endorsements for innovative classes | +0.7% | Global | Medium term (2-4 years) |
| Growing adoption of biosimilar basal insulins | +0.5% | Europe, emerging Asia-Pacific, Latin America | Short term (≤ 2 years) |
Source: Mordor Intelligence
Escalating Global Diabetes Prevalence and Early Diagnosis
More than 828 million adults were living with diabetes in 2024, quadruple the 1990 level[2]Pan American Health Organization, “Urgent Action Needed as Global Diabetes Cases Increase Fourfold over the Past Decades,” Pan American Health Organization, paho.org. Earlier screening programs in lower-income regions are enlarging the treated population and lengthening therapy duration [3]American Diabetes Association, “Standards of Care in Diabetes—2025,” American Diabetes Association, diabetes.org. New WHO guidance endorsing earlier use of GLP-1 agonists signals tighter integration of advanced injectables into first-line care. The overlap between obesity and diabetes further amplifies demand because many GLP-1 drugs now carry dual indications. These shifts collectively underpin long-run volume growth for the diabetes drugs market.
Rising Healthcare Expenditures
Pharmaceutical spending on diabetes climbed 19% in 2023, outpacing overall health inflation [4]Eric Tichy et al., “National Trends in Prescription Drug Expenditures and Projections for 2024,” American Journal of Health-System Pharmacy, oxfordacademic.com. Payers are funding costlier therapies because lower complication rates offset near-term outlays. Employer health plans face mounting pressure, driving tighter utilization management yet preserving access to high-value medicines. This spending momentum sustains price realization even as unit costs come under scrutiny, benefiting innovative products that demonstrate clear clinical and economic returns.
Growing Adoption of Biosimilar Basal Insulins
Biosimilar insulin glargine now averages 26% market share five years post-launch, delivering 42% price declines per unit. Lower costs expand treatment access, particularly in price-sensitive regions. Originators are responding with dual-pricing strategies and device enhancements, fostering a more competitive but larger volume base that lifts overall market value.
Rise of Combination Fixed-Dose Pens Enhancing Adherence
Fixed-ratio injectables such as insulin degludec / liraglutide reduce daily injection burden and dosing errors, improving persistence. Clinical evidence shows superior HbA1c reduction and lower hypoglycemia risk versus separate components. Physicians increasingly adopt these pens for patients requiring therapy intensification, supporting incremental value growth within the diabetes drugs market.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Safety Concerns on GLP-1-Linked Pancreatitis | -0.4% | Global | Medium term (2-4 years) |
| Public-Sector Price Caps on Insulin Analogues | -0.3% | North America, Europe | Short term (≤ 2 years) |
| Cold-Chain Infrastructure Gaps Limiting Uptake | -0.2% | Emerging markets in Asia-Pacific, Africa, and parts of Latin America | Medium term (2-4 years) |
| Affordability of Drugs in Emerging Economies | -0.3% | Asia-Pacific, Africa, Latin America, and Middle East | Long term (≥ 4 years) |
Source: Mordor Intelligence
Safety Concerns on GLP-1-Linked Pancreatitis
Isolated pancreatitis reports have prompted enhanced pharmacovigilance and conservative patient selection. Although incidence rates remain low, prescriber caution may slow uptake in high-risk cohorts, moderating the meteoric rise of GLP-1 sales. Manufacturers are supporting education and post-marketing surveillance to safeguard benefit-risk profiles.
Public-Sector Price Caps on Insulin Analogues
Legislation capping monthly insulin out-of-pocket costs compresses margins and shapes global reference pricing. While affordability boosts volume, revenue growth is tempered, pushing companies toward premium formulations and diversified portfolios less exposed to price regulation.
Segment Analysis
By Drugs: GLP-1 Agonists Redefine Treatment Paradigms
Insulin maintained a 55% share of the diabetes drugs market in 2024, underscoring its central role in both Type 1 and advanced Type 2 management. However, GLP-1 receptor agonists are expanding at a 4.5% CAGR, propelled by weight-loss efficacy that broadens prescribing beyond traditional glycemic control. The diabetes drugs market size for GLP-1 products is projected to reach USD 150 billion by 2030, reflecting their dual-indication appeal. Oral SGLT-2 inhibitors continue to gain favor, supported by organ-protective data that positions them as valuable adjuncts or alternatives to injectables.
Competitive dynamics within this segment are intense. Novo Nordisk and Eli Lilly currently hold an estimated near-total share, yet a pipeline of dual and triple agonists promises fresh competition. Fixed-dose combinations, such as insulin degludec / liraglutide pens, illustrate how delivery innovation can lock in adherence benefits and extend product life cycles within the diabetes drugs industry.
Note: Segment shares of all individual segments available upon report purchase
By Route of Administration: Subcutaneous Dominance Challenged by Oral Innovations
Subcutaneous delivery commanded 72% of diabetes drugs market size in 2024 owing to the prevalence of injectable insulins and GLP-1 agents. Smart pens and automated insulin delivery systems are easing administration and refining dose accuracy, reinforcing the route’s incumbency. Notwithstanding, development of transdermal alternatives and once-weekly basal options is widening patient choice.
Oral administration is forecast to expand at a 4.8% CAGR through 2030 as absorption-enhancer and nanoparticle platforms unlock the viability of peptide medicines taken by mouth. Successful commercialization would allow patients to avoid routine injections, potentially reshaping loyalty patterns in the diabetes drugs market. Intravenous and inhaled routes remain niche, reserved for acute or specialized settings where rapid pharmacokinetics outweigh convenience considerations.
By Distribution Channel: Digital Transformation Reshapes Access Patterns
Offline pharmacies held 88% of sales in 2024, reflecting cold-chain demands and pharmacist counseling needs for complex injectable regimens. Hospital pharmacies remain the launchpad for therapy initiation and titration, while community outlets dominate maintenance dispensing.
Online channels, though nascent, are growing at a 4.9% CAGR. Integration with telehealth and subscription models boosts refill compliance for chronic regimens typical of the diabetes drugs market. Pricing transparency and doorstep delivery resonate with digitally engaged consumers, yet regulatory differences by country continue to influence penetration rates. In practice, many patients blend online refills with periodic in-person visits to manage dosage adjustments and device training.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
North America retained leadership with a 42% contribution to 2024 revenue. Broad insurance coverage, strong specialty-care infrastructure, and early adoption of GLP-1 agents underpin regional dominance. Insulin affordability legislation has also stimulated unit demand by lowering patient cost exposure, even as it constrains price expansion. Employers are refining prior-authorization protocols to manage GLP-1 growth, but sustained clinical value is preserving broad access.
Asia-Pacific is the fastest-growing territory, registering a projected 5.3% CAGR from 2025-2030. Rising urbanization, dietary shifts, and aging populations are driving a steep rise in Type 2 prevalence. Expanded insurance benefits in China and India are widening access to branded insulins and novel injectables. Digital health tools and mobile platforms are bridging care-delivery gaps, supporting adherence and continuity for patients in remote areas. The diabetes drugs market size in Asia-Pacific is therefore expected to close part of the gap with entrenched Western markets by 2030.
Europe presents a mature but evolving landscape shaped by robust biosimilar frameworks and value-assessment bodies that scrutinize cost-effectiveness. High biosimilar penetration is pressuring originator pricing, yet uptake of combination devices and advanced GLP-1 agents is supporting revenue resilience. Emerging markets in the Middle East and Latin America add incremental opportunity as governments commit funds to address escalating diabetes prevalence and as multinational firms localize manufacturing and distribution.
Competitive Landscape
The diabetes drugs market is moderately concentrated, with the top five companies capturing a substantial revenue pool. Novo Nordisk and Eli Lilly dominate GLP-1 therapies and hold strong basal-insulin franchises. Sanofi sustains relevance through long-standing analogs and a growing biosimilar pipeline. Strategic acquisitions, such as Novo Nordisk’s purchase of Catalent, highlight the premium placed on manufacturing scalability for high-volume injectables.
Competition is shifting toward multi-receptor agonists and oral peptide formats that promise superior efficacy or convenience. Amgen, Roche, and several mid-cap innovators are advancing dual or triple agonists targeting GLP-1, GIP, and glucagon receptors, aiming to erode incumbent share. Technology partnerships are multiplying; device-software ecosystems linking continuous glucose monitoring with automated dosing algorithms are becoming key differentiators.
Pricing pressure from biosimilars and public-sector caps is encouraging originators to bundle drugs with digital services, value-based contracts, and adherence programs. Portfolio strategies increasingly straddle diabetes and obesity, leveraging shared metabolic pathways to maximize lifetime value per patient. The diabetes drugs industry therefore rewards firms that can deliver holistic solutions rather than single-product offerings.
Diabetes Drugs Industry Leaders
-
Novo Nordisk
-
Sanofi
-
AstraZeneca
-
Boehringer Ingelheim
-
Eli Lilly and Company
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- March 2025: Eli Lilly confirmed plans to introduce Mounjaro in China, India, Brazil, and Mexico by 2026, targeting large unmet demand for dual diabetes-obesity therapy.
- March 2025: Novo Nordisk secured FDA approval for CagriSema, a dual GLP-1/GIP agonist projected to generate USD 8.3 billion in annual sales by 2030.
- February 2025: The FDA cleared Merilog (insulin-aspart-szjj), the first rapid-acting biosimilar to Novolog, broadening affordable options for mealtime control.
- May 2024: Sanofi India launched Soliqua, a fixed-dose insulin glargine / lixisenatide pen, priced at INR 1,850 (USD 22.3) per 3 ml prefilled device.
- January 2024: Tandem Diabetes Care announced integration of Abbott’s FreeStyle Libre 3 Plus sensor with its insulin pumps, enabling automated insulin delivery from 2025.
Global Diabetes Drugs Market Report Scope
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin the body's cells do not respond properly to insulin, or both.
The diabetes care drugs market is segmented by drugs into insulin (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, and insulin biosimilars), oral anti-diabetic drugs (alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), non-insulin injectable drugs (GLP-1 receptor agonists, and amylin analog), and combination drugs (combination insulin, oral combination). by Route of Administration (Oral, Intravenous, Subcutaneous), by Distribution Channel (Online, and Offline), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The report offers the value (in USD) and Volume (in ml) for the above segments.
| By Drugs | Oral Anti-diabetic Drugs | Biguanides | Metformin | |
| Alpha-glucosidase Inhibitors | ||||
| Dopamine-D2 Receptor Agonist | Cycloset (Bromocriptine) | |||
| SGLT-2 Inhibitors | Invokana (Canagliflozin) | |||
| Jardiance (Empagliflozin) | ||||
| Farxiga/Forxiga (Dapagliflozin) | ||||
| Suglat (Ipragliflozin) | ||||
| DPP-4 Inhibitors | Januvia (Sitagliptin) | |||
| Onglyza (Saxagliptin) | ||||
| Tradjenta (Linagliptin) | ||||
| Vipidia/Nesina (Alogliptin) | ||||
| Galvus (Vildagliptin) | ||||
| Sulfonylureas | ||||
| Meglitinides | ||||
| Insulin | Basal / Long-acting | Lantus (Insulin Glargine) | ||
| Levemir (Insulin Detemir) | ||||
| Toujeo (Insulin Glargine) | ||||
| Tresiba (Insulin Degludec) | ||||
| Basaglar (Insulin Glargine) | ||||
| Bolus / Fast-acting | NovoRapid/Novolog (Insulin Aspart) | |||
| Humalog (Insulin Lispro) | ||||
| Apidra (Insulin Glulisine) | ||||
| Traditional Human Insulin | Novolin/Actrapid/Insulatard | |||
| Humulin | ||||
| Insuman | ||||
| Biosimilar Insulin | Insulin Glargine Biosimilars | |||
| Human Insulin Biosimilars | ||||
| Non-insulin Injectable Drugs | GLP-1 Receptor Agonists | Victoza (Liraglutide) | ||
| Byetta (Exenatide) | ||||
| Bydureon (Exenatide) | ||||
| Trulicity (Dulaglutide) | ||||
| Lyxumia (Lixisenatide) | ||||
| Amylin Analogue | Symlin (Pramlintide) | |||
| Combination Drug | Combination Insulin | NovoMix (Biphasic Insulin Aspart) | ||
| Ryzodeg (Insulin Degludec + Aspart) | ||||
| Xultophy (Insulin Degludec + Liraglutide) | ||||
| Oral Combination | Janumet (Sitagliptin + Metformin) | |||
| By Route of Administration | Oral | |||
| Subcutaneous | ||||
| Intravenous | ||||
| By Distribution Channel | Online Pharmacies | |||
| Offline (Hospital & Retail Pharmacies) | ||||
| By Geography | North America | United States | ||
| Canada | ||||
| Mexico | ||||
| Europe | Germany | |||
| United Kingdom | ||||
| France | ||||
| Italy | ||||
| Spain | ||||
| Rest of Europe | ||||
| Asia-Pacific | China | |||
| Japan | ||||
| India | ||||
| South Korea | ||||
| Australia | ||||
| Rest of Asia-Pacific | ||||
| Middle East | GCC | |||
| South Africa | ||||
| Rest of Middle East | ||||
| South America | Brazil | |||
| Argentina | ||||
| Rest of South America | ||||
By Drugs
| Oral Anti-diabetic Drugs | Biguanides | Metformin | |
| Alpha-glucosidase Inhibitors | |||
| Dopamine-D2 Receptor Agonist | Cycloset (Bromocriptine) | ||
| SGLT-2 Inhibitors | Invokana (Canagliflozin) | ||
| Jardiance (Empagliflozin) | |||
| Farxiga/Forxiga (Dapagliflozin) | |||
| Suglat (Ipragliflozin) | |||
| DPP-4 Inhibitors | Januvia (Sitagliptin) | ||
| Onglyza (Saxagliptin) | |||
| Tradjenta (Linagliptin) | |||
| Vipidia/Nesina (Alogliptin) | |||
| Galvus (Vildagliptin) | |||
| Sulfonylureas | |||
| Meglitinides | |||
| Insulin | Basal / Long-acting | Lantus (Insulin Glargine) | |
| Levemir (Insulin Detemir) | |||
| Toujeo (Insulin Glargine) | |||
| Tresiba (Insulin Degludec) | |||
| Basaglar (Insulin Glargine) | |||
| Bolus / Fast-acting | NovoRapid/Novolog (Insulin Aspart) | ||
| Humalog (Insulin Lispro) | |||
| Apidra (Insulin Glulisine) | |||
| Traditional Human Insulin | Novolin/Actrapid/Insulatard | ||
| Humulin | |||
| Insuman | |||
| Biosimilar Insulin | Insulin Glargine Biosimilars | ||
| Human Insulin Biosimilars | |||
| Non-insulin Injectable Drugs | GLP-1 Receptor Agonists | Victoza (Liraglutide) | |
| Byetta (Exenatide) | |||
| Bydureon (Exenatide) | |||
| Trulicity (Dulaglutide) | |||
| Lyxumia (Lixisenatide) | |||
| Amylin Analogue | Symlin (Pramlintide) | ||
| Combination Drug | Combination Insulin | NovoMix (Biphasic Insulin Aspart) | |
| Ryzodeg (Insulin Degludec + Aspart) | |||
| Xultophy (Insulin Degludec + Liraglutide) | |||
| Oral Combination | Janumet (Sitagliptin + Metformin) | ||
By Route of Administration
| Oral |
| Subcutaneous |
| Intravenous |
By Distribution Channel
| Online Pharmacies |
| Offline (Hospital & Retail Pharmacies) |
By Geography
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| South Korea | |
| Australia | |
| Rest of Asia-Pacific | |
| Middle East | GCC |
| South Africa | |
| Rest of Middle East | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
How big is the Diabetes Drugs Market?
The Diabetes Drugs Market size is expected to reach USD 90.60 billion in 2025 and grow at a CAGR of 3.51% to reach USD 107.66 billion by 2030.
What is the current Diabetes Drugs Market size?
The diabetes drugs market generated USD 90.6 billion in 2025 and is projected to reach USD 107.66 billion by 2030.
Which therapy class is growing fastest?
GLP-1 receptor agonists lead growth with a 4.5% CAGR thanks to combined glycemic and weight-loss benefits.
How big is North America’s role in global sales?
North America accounted for 42% of 2024 revenue, underpinned by high prevalence and early adoption of advanced therapies.
What impact do biosimilar insulins have on prices?
Biosimilar insulin glargine has driven a 42% decline in per-unit pricing while raising market volume.
